Bolt Biotherapeutics (BOLT) Non Operating Income (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Non Operating Income of $357000.0 for Q1 2026, down 21.37% sequentially from $454000.0 in Q4 2025, and down 66.79% YoY from $1.1 million in Q1 2025.
Bolt Biotherapeutics (BOLT) Non Operating Income (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Non Operating Income for 7 years, with the latest figure at $357000.0 in Q1 2026.
- Quarterly Non Operating Income fell 66.79% year-over-year to $357000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 57.26% YoY) and the FY2025 annual result came in at $2.7 million, down 72.44% from the prior year.
- Non Operating Income eased to $357000.0 in Q1 2026 per BOLT's latest filing, from $454000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $6.3 million in Q1 2024 and troughed at $198000.0 in Q1 2022.
- A 5-year average of $1.3 million and a median of $1.0 million in 2022 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2025: Non Operating Income jumped 1371.95% in 2022, then plunged 82.88% in 2025.
- Over 5 years, Non Operating Income stood at $1.0 million in 2022, then soared by 78.62% to $1.9 million in 2023, then sank by 47.4% to $980000.0 in 2024, then plunged by 53.67% to $454000.0 in 2025, then slipped by 21.37% to $357000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $357000.0, $454000.0, and $559000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Bolt Biotherapeutics | 6.10 Mn | 6.10 Mn | - | 654,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 654,000.00 |
| Mar 31, 2026 | 357,000.00 |
| Dec 31, 2025 | 454,000.00 |
| Sep 30, 2025 | 559,000.00 |
| Jun 30, 2025 | 649,000.00 |
| Mar 31, 2025 | 1.08 Mn |
| Dec 31, 2024 | 980,000.00 |
| Sep 30, 2024 | 1.27 Mn |
| Jun 30, 2024 | 1.40 Mn |
| Mar 31, 2024 | 6.28 Mn |
| Dec 31, 2023 | 1.86 Mn |
| Sep 30, 2023 | 1.93 Mn |
| Jun 30, 2023 | 1.78 Mn |
| Mar 31, 2023 | 1.44 Mn |
| Dec 31, 2022 | 1.04 Mn |
| Sep 30, 2022 | 587,000.00 |
| Jun 30, 2022 | 395,000.00 |
| Mar 31, 2022 | 198,000.00 |
| Dec 31, 2021 | -82,000.00 |
| Sep 30, 2021 | 131,000.00 |